171 related articles for article (PubMed ID: 35613082)
21. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
22. An open label pilot study of the safety and tolerability of perampanel in amyotrophic lateral sclerosis.
Hotait M; Ismail HH; Saab GE; Salameh JS
Muscle Nerve; 2021 Oct; 64(4):504-508. PubMed ID: 34322897
[TBL] [Abstract][Full Text] [Related]
23. Open label study to assess the safety of VM202 in subjects with amyotrophic lateral sclerosis.
Sufit RL; Ajroud-Driss S; Casey P; Kessler JA
Amyotroph Lateral Scler Frontotemporal Degener; 2017 May; 18(3-4):269-278. PubMed ID: 28166654
[TBL] [Abstract][Full Text] [Related]
24. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
Henderson RD; Agosti JM; McCombe PA; Thorpe K; Heggie S; Heshmat S; Appleby MW; Ziegelaar BW; Crowe DT; Redlich GL
Medicine (Baltimore); 2021 Oct; 100(42):e27421. PubMed ID: 34678870
[TBL] [Abstract][Full Text] [Related]
25. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis.
Nicholson K; Chan J; Macklin EA; Levine-Weinberg M; Breen C; Bakshi R; Grasso DL; Wills AM; Jahandideh S; Taylor AA; Beaulieu D; Ennist DL; Andronesi O; Ratai EM; Schwarzschild MA; Cudkowicz M; Paganoni S
Ann Clin Transl Neurol; 2018 Dec; 5(12):1522-1533. PubMed ID: 30564619
[TBL] [Abstract][Full Text] [Related]
26. A pilot trial of RNS60 in amyotrophic lateral sclerosis.
Paganoni S; Alshikho MJ; Luppino S; Chan J; Pothier L; Schoenfeld D; Andres PL; Babu S; Zürcher NR; Loggia ML; Barry RL; Luotti S; Nardo G; Trolese MC; Pantalone S; Bendotti C; Bonetto V; De Marchi F; Rosen B; Hooker J; Cudkowicz M; Atassi N
Muscle Nerve; 2019 Mar; 59(3):303-308. PubMed ID: 30458059
[TBL] [Abstract][Full Text] [Related]
27. VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics.
Andrews JA; Cudkowicz ME; Hardiman O; Meng L; Bian A; Lee J; Wolff AA; Malik FI; Shefner JM
Amyotroph Lateral Scler Frontotemporal Degener; 2018 May; 19(3-4):259-266. PubMed ID: 29402141
[TBL] [Abstract][Full Text] [Related]
28. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
[TBL] [Abstract][Full Text] [Related]
29. Autologous bone marrow-derived stem cells in amyotrophic lateral sclerosis: a pilot study.
Prabhakar S; Marwaha N; Lal V; Sharma RR; Rajan R; Khandelwal N
Neurol India; 2012; 60(5):465-9. PubMed ID: 23135021
[TBL] [Abstract][Full Text] [Related]
30. DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial.
McDermott CJ; Bradburn MJ; Maguire C; Cooper CL; Baird WO; Baxter SK; Cohen J; Cantrill H; Dixon S; Ackroyd R; Baudouin S; Bentley A; Berrisford R; Bianchi S; Bourke SC; Darlison R; Ealing J; Elliott M; Fitzgerald P; Galloway S; Hamdalla H; Hanemann CO; Hughes P; Imam I; Karat D; Leek R; Maynard N; Orrell RW; Sarela A; Stradling J; Talbot K; Taylor L; Turner M; Simonds AK; Williams T; Wedzicha W; Young C; Shaw PJ
Health Technol Assess; 2016 Jun; 20(45):1-186. PubMed ID: 27353839
[TBL] [Abstract][Full Text] [Related]
31. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.
Arch Neurol; 1996 Feb; 53(2):141-7. PubMed ID: 8639063
[TBL] [Abstract][Full Text] [Related]
32. Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial.
Al-Chalabi A; Shaw P; Leigh PN; van den Berg L; Hardiman O; Ludolph A; Aho VV; Sarapohja T; Kuoppamäki M
J Neurol Neurosurg Psychiatry; 2019 Oct; 90(10):1165-1170. PubMed ID: 31315908
[TBL] [Abstract][Full Text] [Related]
33. Nutritional counseling with or without mobile health technology: a randomized open-label standard-of-care-controlled trial in ALS.
Wills AM; Garry J; Hubbard J; Mezoian T; Breen CT; Ortiz-Miller C; Nalipinski P; Sullivan S; Berry JD; Cudkowicz M; Paganoni S; Chan J; Macklin EA
BMC Neurol; 2019 May; 19(1):104. PubMed ID: 31142272
[TBL] [Abstract][Full Text] [Related]
34. G-CSF prevents the progression of structural disintegration of white matter tracts in amyotrophic lateral sclerosis: a pilot trial.
Duning T; Schiffbauer H; Warnecke T; Mohammadi S; Floel A; Kolpatzik K; Kugel H; Schneider A; Knecht S; Deppe M; Schäbitz WR
PLoS One; 2011 Mar; 6(3):e17770. PubMed ID: 21423758
[TBL] [Abstract][Full Text] [Related]
35. A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C).
Kindy M; Lupinacci P; Chau R; Shum T; Ko D
F1000Res; 2017; 6():230. PubMed ID: 30057745
[No Abstract] [Full Text] [Related]
36. Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 18 STUDY GROUP
Amyotroph Lateral Scler Frontotemporal Degener; 2017 Oct; 18(sup1):40-48. PubMed ID: 28872915
[TBL] [Abstract][Full Text] [Related]
37. Rapamycin treatment for amyotrophic lateral sclerosis: Protocol for a phase II randomized, double-blind, placebo-controlled, multicenter, clinical trial (RAP-ALS trial).
Mandrioli J; D'Amico R; Zucchi E; Gessani A; Fini N; Fasano A; Caponnetto C; Chiò A; Dalla Bella E; Lunetta C; Mazzini L; Marinou K; Sorarù G; de Biasi S; Lo Tartaro D; Pinti M; Cossarizza A;
Medicine (Baltimore); 2018 Jun; 97(24):e11119. PubMed ID: 29901635
[TBL] [Abstract][Full Text] [Related]
38. Safety and Efficacy of Allogeneic Adipose Tissue Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosis Patients, Single-Center, Prospective, Open-Label, Single-Arm Clinical Trial, Long-Term Follow-up.
Nabavi SM; Karimi SH; Arab L; Sanjari L; Mardpour S; Azimian V; Jarughi N; Ghaheri A; Hosseini SE; Aghdami N; Vosough M
Cell J; 2021 Dec; 23(7):772-778. PubMed ID: 34979067
[TBL] [Abstract][Full Text] [Related]
39. Safety, Tolerability, and Pharmacodynamics of Intrathecal Injection of Recombinant Human HGF (KP-100) in Subjects With Amyotrophic Lateral Sclerosis: A Phase I Trial.
Warita H; Kato M; Asada R; Yamashita A; Hayata D; Adachi K; Aoki M
J Clin Pharmacol; 2019 May; 59(5):677-687. PubMed ID: 30536581
[TBL] [Abstract][Full Text] [Related]
40. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study.
Blanquer M; Moraleda JM; Iniesta F; Gómez-Espuch J; Meca-Lallana J; Villaverde R; Pérez-Espejo MÁ; Ruíz-López FJ; García Santos JM; Bleda P; Izura V; Sáez M; De Mingo P; Vivancos L; Carles R; Jiménez J; Hernández J; Guardiola J; Del Rio ST; Antúnez C; De la Rosa P; Majado MJ; Sánchez-Salinas A; López J; Martínez-Lage JF; Martínez S
Stem Cells; 2012 Jun; 30(6):1277-85. PubMed ID: 22415951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
